Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
October 2016

Stimulants for ADHD: Tracking Two Adverse Events
For children and adolescents with ADHD, stimulant treatment is associated with an increased risk of cardiovascular events and a decreased risk of anxiety.

Long-Term Effects of Antidepressants on Weight
Bupropion (Wellbutrin and others) may be the most appropriate first-line treatment for depressed patients concerned about long-term weight gain.

Two Antipsychotic Warnings from the FDA
The FDA has issued warnings about a rare but serious skin reaction with olanzapine (Zyprexa and others) and the development of impulse-control problems with aripiprazole (Abilify and others).

Milnacipran and Levomilnacipran
There are few clinically relevant differences between milnacipran (Savella) and its levo enantiomer levomilnacipran (Fetzima).

In Brief
In an Animal Trial, Exercise Increased Production of Brain-Derived Neurotrophic Factor; Exercise Improves Cognitive Function in Patients with Schizophrenia

Anticholinergic Drugs Raise Fracture Risk
Anticholinergic drugs should be avoided in older people for many reasons, including an increased risk of fractures.

A Message from Alan J. Gelenberg, M.D.

When I first started writing BTP in the 1970s, it was to bridge the gap between new knowledge in our field and its application to patient care. Over the decades since, the need for this bridge has become even greater. Neuroscience rockets forward. Psychiatrists and other clinicians have a broader array of treatments for patients with mental disorders than we even dreamed of back then. But we have less time to spend with patients and less time to keep up with developments that affect treatment decisions. Our medications, and those prescribed by colleagues in other specialties, are more varied, complex, and prone to interactions. What were formerly crisp boundaries between major psychopharmacologic categories are now murky.

This makes the modern practice of psychiatry challenging—but also fun and promising. With the expanding armamentarium of treatment options comes enhanced ability to alleviate suffering. The mission of BTP remains constant, even while the field grows. We are still here to bridge the gap, to make science applicable and relevant, and to help you in your day-to-day work relieve distress and improve function in patients' lives.